Adco Cefazolin Injection
PDF Leaflet Revision Date: 13 March 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infections and pre-exposure prophylaxis (PrEP) in HIV-negative adults.
Dosage (summary)
One tablet (200 mg emtricitabine and 300 mg tenofovir) once daily.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; avoid breastfeeding due to potential HIV transmission.
Key Drug Interactions
- Nephrotoxic drugs
- Ledipasvir/sofosbuvir
Contraindications
- Hypersensitivity to components
- Creatinine clearance < 60 mL/min for PrEP
- Pregnancy
- Breastfeeding
Common side effects
- Nausea
- Diarrhoea
- Headache
- Fatigue
Counselling Points
- Adhere strictly to dosing schedule
- Monitor for signs of acute HIV infection
- Regular HIV testing every 3 months during PrEP
Serious warnings
- Lactic acidosis
- Severe hepatomegaly
- Risk of renal impairment
Important Disclaimer
The Adco Cefazolin Injection professional information leaflet below is the property of Adcock Ingram Critical Care and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
